Global Edition
Global Edition
UK Edition
EU Edition
US Edition

Understand the story, not the spin.

Markets

Daraxonrasib combination shrinks tumours in pancreatic cancer trial

Published 20 November 2026 · All stories from this day

A daily daraxonrasib pill combined with chemotherapy was associated with tumour shrinkage or disappearance in 60.7% of 61 patients with advanced pancreatic cancer, according to trial results presented in Barcelona. Cancer was undetectable on scans in 8.2% of participants, researchers reported, while the treatment kept the disease from progressing in 90.2%. The findings do not establish that the combination cures cancer or improves survival compared with standard chemotherapy.

The trial enrolled people whose pancreatic cancer had spread to other parts of the body. Patients received daraxonrasib alongside the chemotherapy drugs gemcitabine and nab-paclitaxel. Researchers reported that 76.6% of participants were alive 12 months after starting treatment. That figure compares with historical one-year survival rates of 40% to 45% for patients receiving chemotherapy alone, but the trial did not directly compare the treatments.

The study involved 61 patients and did not have a randomized control group. Researchers and outside cancer specialists cautioned that the results cannot show whether the drug combination extends life compared with chemotherapy alone, or how long responses will...

Now playing
0:00 / 0:00